PMCB · PharmaCyte Biotech, Inc. · Insider Trading

The reported grant was made in error and has been cancelled.

The reported grant was made in error and has been cancelled.

The reported grant was made in error and has been cancelled.

The reported grant was made in error and has been cancelled.

Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction.

Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction.

Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction.

Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction.

Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction.

The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Walker. This transaction is late due to an inadvertent administrative error and not any error of Mr. Walker.

The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Weinstein. This transaction is late due to an inadvertent administrative error and not any error of Mr. Weinstein.

The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Schechter. This transaction is late due to an inadvertent administrative error and not any error of Mr. Schechter.

The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Abecassis. This transaction is late due to an inadvertent administrative error and not any error of Mr. Abecassis.

The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Schechter. This transaction is late due to an inadvertent administrative error and not any error of Mr. Schechter.

The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Weinstein. This transaction is late due to an inadvertent administrative error and not any error of Mr. Weinstein.

The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Abecassis. This transaction is late due to an inadvertent administrative error and not any error of Mr. Abecassis.

The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Walker. This transaction is late due to an inadvertent administrative error and not any error of Mr. Walker.

The options vest 50% on November 20, 2023 and 50% on November 20, 2024.

The options vest 50% on November 20, 2023 and 50% on November 20, 2024.

The option grant was approved by the Issuer's board of directors on November 14, 2022, subject to stockholder approval of the PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan (the "2022 Plan"), under which the option was granted. The Issuer's stockholders approved the 2022 Plan on December 28, 2022.

The option grant was approved by the Issuer's board of directors on November 14, 2022, subject to stockholder approval of the PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan (the "2022 Plan"), under which the option was granted. The Issuer's stockholders approved the 2022 Plan on December 28, 2022.